American Society of Addiction Medicine
American Society of Addiction Medicine
Lead: Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial
Lead: Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial
Lead: Oral methadone versus sublingual buprenorphine for the treatment of acute opioid withdrawal: A triple-blind, double-dummy, randomized control trial
Tuesday 12th August 2025
Explore the effectiveness of methadone vs buprenorphine for opioid withdrawal in this engaging podcast episode.
5 minutes
Informative
Educational
Supportive
Engaging
Eye-opening
About this podcast
Author:
American Society of Addiction Medicine
Overview:
Categories:
Innovative Treatments & Recovery Paths
Navigating Alcohol Dependency
Family Recovery from Addiction
Nutritional Pathways to Recovery
Navigating Intimate Relationships
Links:
Visit site
Episodes:
178 (View all)
Do you want to link to this podcast?
Get the buttons here!Methadone vs Buprenorphine: A Study on Opioid Withdrawal
Episode Overview
- Methadone shows slightly better results than buprenorphine for opioid withdrawal.
- Contingency Management programs can be effective but face privacy concerns.
- Fentanyl-related cardiac arrests have unique challenges compared to other opioids.
- Fentanyl possession laws may not reduce overdose deaths.
- Prescription stimulant use trends among adolescents show changing patterns.
"Methadone is a safe and effective alternative to buprenorphine for management of opioid withdrawal"
If you've ever wondered about the effectiveness of oral methadone versus sublingual buprenorphine for treating acute opioid withdrawal, this episode of 'This Week in Addiction Medicine from ASAM' is a must-listen. The podcast dives into a fascinating study conducted in India, where patients were randomly assigned to receive either methadone or buprenorphine at an inpatient drug treatment centre.
The study found that both treatments were effective in reducing withdrawal symptoms, but methadone had a slight edge over buprenorphine by the end of the treatment. Both medications were tapered off by day 11, with completion rates nearly identical for both groups. You'll also hear about a pilot Contingency Management (CM) programme for stimulant use disorder among homeless veterans in Los Angeles.
Despite privacy concerns and stigma, participants appreciated the programme's support and immediate rewards, suggesting it could be beneficial in community settings. Another segment discusses fentanyl-related cardiac arrests, revealing that these cases have lower rates of bystander CPR and shockable rhythms compared to other opioid-related incidents. The podcast also tackles the controversial topic of fentanyl possession laws in Colorado and their impact on opioid overdose deaths. The episode rounds off with insights into trends in prescription stimulant use among U.S.
adolescents and the worrying rise in nitrous oxide-related mortality. This episode is packed with data-driven discussions that provide valuable information for anyone interested in addiction medicine. Whether you're seeking knowledge or solutions, you'll find this episode both informative and engaging. So why not dive into these important discussions today?